journal article·2009-03-15

Short‐, mid‐, and long‐term effects of a polymer‐free tacrolimus‐eluting stent in a porcine coronary model

M. Prunotto, C. Vignolini, V. Lolli, A. Black, S. Gaggianesi, A. Santarelli, M. Galloni

Publisher page

Abstract

Abstract Stent‐based delivery of tacrolimus has shown neointimal hyperplasia and restenosis reduction; FK506 is a water insoluble macrolide immunosuppressant. The purpose of this study was to evaluate acute and chronic tissue response to a polymer‐free FK506 drug‐eluting stent implantation in a porcine coronary artery model. Seventy‐eight nonatherosclerotic minipigs underwent successful placement of 134 stents (control n = 56; FK506 (1.5 μg/mm2) n = 44; FK506 (2.6 μg/mm2) n = 34) at 7, 15, 30, 90, or 180 days. Endothelialisation was almost complete at 7 days, complete at 15 days. At 30 and 90 days, mean neointimal thickness, neointimal area, and % stenosis was significantly less for drug‐eluting stents compared with controls. At 180 days, histomorphometric values were similar for eluting and control stents. The FK506‐eluting stent allows for a complete re‐endothelialisation at 15 days and favorably moderate neointimal hyperplasia at 30 and 90 days in the porcine coronary model. Because of a possible limited bioavailability of FK506, long‐term inhibition of neointimal formation was not sustained at the considered follow‐up. © 2008 Wiley Periodicals, Inc. J Biomed Mater Res, 2009
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Coronary Interventions and Diagnostics · Cardiac Valve Diseases and Treatments · Cardiac and Coronary Surgery Techniques

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (24)

Show source-provided references
1. 10.1056/NEJM19981203339230410.1056/NEJM199812033392304 ↗
2. 10.1056/NEJM19940825331080110.1056/NEJM199408253310801 ↗
3. 10.1016/0735-1097(92)90119-810.1016/0735-1097(92)90119-8 ↗
4. 10.1016/S0735-1097(97)00450-610.1016/S0735-1097(97)00450-6 ↗
5. 10.1161/01.CIR.0000050367.65079.7110.1161/01.CIR.0000050367.65079.71 ↗
6. 10.1161/hc3601.09398710.1161/hc3601.093987 ↗
7. 10.1002/ccd.1066410.1002/ccd.10664 ↗
8. 10.1016/j.cardiores.2004.04.02910.1016/j.cardiores.2004.04.029 ↗
9. 10.1002/ccd.2021310.1002/ccd.20213 ↗
10. 10.1016/j.cardiores.2004.06.01610.1016/j.cardiores.2004.06.016 ↗
11. 10.1097/01.RVI.0000082982.70522.5D10.1097/01.RVI.0000082982.70522.5D ↗
12. 10.1007/s10856-005-4733-410.1007/s10856-005-4733-4 ↗
13. 10.2460/javma.2001.218.66910.2460/javma.2001.218.669 ↗
14. 10.1016/0735-1097(94)90126-010.1016/0735-1097(94)90126-0 ↗
15. 10.3109/1052029860911070810.3109/10520298609110708 ↗
16. 10.1016/0735-1097(92)90476-410.1016/0735-1097(92)90476-4 ↗
17. 10.1056/NEJM19910103324010310.1056/NEJM199101033240103 ↗
18. 10.1007/s00270-001-1729-410.1007/s00270-001-1729-4 ↗
19. 10.1161/01.CIR.0000033973.06059.0410.1161/01.CIR.0000033973.06059.04 ↗
20. Use of a tacrolimus‐eluting stent to inhibit neointimal hyperplasia in a porcine coronary model
21. 10.1097/01.fjc.0000248233.22570.8b10.1097/01.fjc.0000248233.22570.8b ↗
22. 10.1161/01.CIR.94.7.169010.1161/01.CIR.94.7.1690 ↗
23. 10.1016/0021-9150(94)05472-U10.1016/0021-9150(94)05472-U ↗
24. 10.1046/j.1540-8183.2003.01050.x10.1046/j.1540-8183.2003.01050.x ↗